Key facts
- It has raised $10.1M; the latest was Seed Round ($6.5M) in Apr 2025.
- Notable investors include 500 Global, SOSV, IndieBio, Hub71, VentureSouq — 21 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for Proteinea
- ·The full record, as it builds
Funding rounds
No funding rounds for Proteinea are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Proteinea
Developer of a protein engineering platform designed to engineer next-generation antibodies with improved efficacy, safety, and convenience. The company's platform utilizes proprietary artificial intelligence models and computational tools to evaluate the efficacy, yield, safety, and pharmacological properties of biologics, enabling clients to design antibody medicines and focusing on scalable, sustainable, and cost-effective protein production.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2019
- Employees
- 50
- Website
- proteinea.com/
- Ownership
- Privately Held (backing)
Proteinea doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Proteinea shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Proteinea in its N-PORT filings yet. We sweep new filings monthly.